Get the Stockscreener App
8.33
17.99%
1.27
Pre-market:
8.34
0.010
+0.12%
Novavax Inc stock is traded at $8.33, with a volume of 10.41M.
It is up +17.99% in the last 24 hours and down -4.14% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
See More
Previous Close:
$7.06
Open:
$7.165
24h Volume:
10.41M
Relative Volume:
2.53
Market Cap:
$1.33B
Revenue:
$847.25M
Net Income/Loss:
$-284.86M
P/E Ratio:
-3.6376
EPS:
-2.29
Net Cash Flow:
$-112.35M
1W Performance:
+4.26%
1M Performance:
-4.14%
6M Performance:
-32.71%
1Y Performance:
+68.62%
1-Day Range:
$7.08
$8.3982
1-Week Range:
$7.02
$8.3982
52-Week Range:
$3.81
$23.86
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.33 | 1.33B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 123.21B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 31.94B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.00B | 3.32B | -860.46M | -1.04B | -8.32 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates - MSN
Novavax sees royalties, reduced expenses on COVID vaccines from Sanofi partnership - MSN
Novavax, Inc. (NASDAQ:NVAX) Shares Could Be 45% Below Their Intrinsic Value Estimate - Yahoo Finance
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating (NASDAQ:NVAX) - Seeking Alpha
Novavax, Inc. (NASDAQ:NVAX) Q4 2024 Earnings Call Transcript - Insider Monkey
1 Biotech Stock to Buy in 2025, and 1 to Avoid - MSN
Decoding Novavax Inc (NVAX): A Strategic SWOT Insight - GuruFocus.com
Novavax Inc (NVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial ... - Yahoo Finance
Novavax Inc (NVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial ... By GuruFocus - Investing.com Canada
Novavax Reports 2024 Earnings and Strategic Shift - TipRanks
Novavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi Partnership - MSN
Novavax initiated with a Buy at BTIG - TipRanks
Novavax Earnings Call: Strategic Moves and Challenges - TipRanks
Novavax: Q4 Earnings Snapshot - The Advocate
Novavax Looks To Right Its Ship Amid Revenue Slump - Insights
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Novavax Stock: Narrowing Losses Drive Market Confidence - sharewise
Novavax to Participate in Upcoming March Investor Conferences - PR Newswire
Novavax execs lay out 2025 game plan, talk ‘defining moment’ for business - The Business Journals
Novavax rising after reporting narrower Q4 loss, revenue beat - Yahoo Finance
Novavax : manages to reduce losses in 2024 -February 27, 2025 at 11:06 am EST - Marketscreener.com
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value - Yahoo Finance
Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines - MSN
Novavax Inc reports results for the quarter ended December 31Earnings Summary - TradingView
NVAX Earnings: Novavax Stock Jumps Despite Mixed Q4 Results - Markets Insider
Earnings call transcript: Novavax Q4 2024 sees revenue drop, stock rises - Investing.com
Novavax reports large quarterly revenue declines, rethinks its strategic direction - Yahoo Finance
Novavax’s quarterly loss shrinks as it ramps down spending on COVID vaccines By Reuters - Investing.com Canada
Novavax posts Q4 revenue beat despite 80% drop in product sales - MSN
Novavax Q4 Net Loss Narrows, Revenue Falls -February 27, 2025 at 09:12 am EST - Marketscreener.com
Novavax (NVAX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines -February 27, 2025 at 09:08 am EST - Marketscreener.com
Novavax stock on watch after Q4 results (NVAX:NASDAQ) - Seeking Alpha
Novavax Sees Reduced Q4 Losses and Strategic Shifts AheadNews and Statistics - IndexBox, Inc.
Earnings Flash (NVAX) NOVAVAX INC. Posts Q4 Revenue $88.3M, vs. FactSet Est of $84.4M - Marketscreener.com
Novavax: Q4 Earnings Snapshot -February 27, 2025 at 08:19 am EST - Marketscreener.com
Novavax Looks To Sanofi Partnership After Narrowing Quarterly Losses - Finimize
Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights - TradingView
Novavax earnings beat by $0.09, revenue fell short of estimates - Investing.com UK
Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines -February 27, 2025 at 08:06 am EST - Marketscreener.com
Novavax Stock Is Rising. Investors Cheer Revenue Beat, Vaccine Shift. - Barron's
NOVAVAX INC SEC 10-K Report - TradingView
Novavax Retail Traders Stay Bullish Ahead Of Q4 Print Even As RFK Jr's HHS Leadership Causes Ripples - MSN
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Novavax Projects Profitability in 2025 Amid Vaccine Challenges - TradingView
Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action Settlement - ACCESS Newswire
Breakeven Is Near for Novavax, Inc. (NASDAQ:NVAX) - Simply Wall St
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
What's in Store for These 5 Biotech Stocks This Earnings Season? - Nasdaq
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):